Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H1 2018

  • ID: 4479936
  • Report
  • Region: New York
  • 106 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aprea AB
  • CanBas Co Ltd
  • ORCA Therapeutics BV
  • OSE Immunotherapeutics
  • Quark Pharmaceuticals Inc
  • MORE
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H1 2018

Summary:

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Tumor protein p53 also known as p53 is any isoform of a protein encoded by TP53 gene. TP53 gene is the most frequently mutated gene in human cancer indicating that the TP53 gene plays a crucial role in preventing cancer formation.

Activated p53 binds DNA and activates expression of several genes including microRNA miR-34a, WAF1/CIP1 encoding for p21 and hundreds of other down-stream genes. p21 binds to the G1-S/CDK (CDK4/CDK6, CDK2, and CDK1) complexes (molecules important for the G1/S transition in the cell cycle) inhibiting their activity.

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) pipeline Target constitutes close to 22 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 5, 3 and 3 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Genito Urinary System And Sex Hormones, Immunology, Respiratory and Toxicology which include indications Non-Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Ovarian Cancer, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Small-Cell Lung Cancer, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Adenocarcinoma Of The Gastroesophageal Junction, Alopecia, Anaplastic Astrocytoma, Bladder Cancer, Brain Cancer, Brain Tumor, Cervical Cancer, Chemotherapy Effects, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Hematological Tumor, Hepatic - Colorectal Metastasis, Kidney Transplant Rejection, Leukemias, Malignant Pleural Effusion, Metastatic Adenocarcinoma of The Pancreas, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Oligodendroglioma, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Recurrent Medulloblastoma, Refractory Medulloblastoma, Renal Cell Carcinoma, Retinoblastoma and Solid Tumor.

The latest report Cellular Tumor Antigen p53 - Pipeline Review, H1 2018, outlays comprehensive information on the Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
  • The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aprea AB
  • CanBas Co Ltd
  • ORCA Therapeutics BV
  • OSE Immunotherapeutics
  • Quark Pharmaceuticals Inc
  • MORE
Introduction

Report Coverage

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Overview

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Companies Involved in Therapeutics Development

Aprea AB

CanBas Co Ltd

Cotinga Pharmaceuticals Inc

Innovation Pharmaceuticals Inc

ORCA Therapeutics BV

OSE Immunotherapeutics

Quark Pharmaceuticals Inc

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Drug Profiles

APR-246 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AU-14022 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBS-9106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

contusugene ladenovec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

COTI-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-12PGJ3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kevetrin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MHY-449 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MJ-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Viruses to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSE-2101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

p28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPAL-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPI-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGT-53 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate p53 for Oncology and Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZMC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Dormant Products

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Discontinued Products

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Product Development Milestones

Featured News & Press Releases

Feb 27, 2018 : OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

Feb 08, 2018 : Innovation Pharmaceuticals Concludes Successful Phase 2a Trial of Kevetrin for Ovarian Cancer; Intra-Tumor Modulation of p53 Observed

Jan 25, 2018 : Cotinga Pharmaceuticals Announces Publication of Positive Data from Preclinical Study of COTI-2 in PLOS One

Jan 25, 2018 : OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi in Immuno-Oncology Applications

Dec 27, 2017: Innovation Pharmaceuticals Obtains Direct Evidence of Molecular Pathways Modulation in Tumors from First Patients in Kevetrin Ph2a Ovarian Cancer Trial

Dec 19, 2017: Critical Outcome Technologies Announces Pharmacodynamic Data and Positive Signals of Efficacy from Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies

Dec 07, 2017: OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

Nov 15, 2017: Critical Outcome Technologies Announces Pharmacokinetic Data From Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies

Nov 07, 2017: Quark Pharmaceuticals to Present Positive Phase 2 Efficacy And Safety Results Of QPI-1002, A siRNA Targeting p53, For Prevention Of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES Conference

Nov 04, 2017: Quark Pharmaceuticals Presents Results from a Positive Phase 2 Study of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery at the American Society of Nephrology Meeting

Nov 01, 2017: Quark Pharmaceuticals Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting

Oct 16, 2017: Karolinska Developments portfolio company Aprea announces first patient enrolled in clinical phase 1b/2 study with APR-246 for the treatment of esophageal cancer

Oct 11, 2017: Critical Outcome Technologies Announces First Patient Dosed in Phase 1 Trial of COTI-2 in Head and Neck Squamous Cell Carcinoma

Sep 14, 2017: Innovation Pharmaceuticals Opens New Clinical Site for Novel p53 Drug Candidate in Phase 2 Ovarian Cancer Trial

Sep 11, 2017: Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Aprea AB, H1 2018

Pipeline by CanBas Co Ltd, H1 2018

Pipeline by Cotinga Pharmaceuticals Inc, H1 2018

Pipeline by Innovation Pharmaceuticals Inc, H1 2018

Pipeline by ORCA Therapeutics BV, H1 2018

Pipeline by OSE Immunotherapeutics, H1 2018

Pipeline by Quark Pharmaceuticals Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

Dormant Products, H1 2018 (Contd..3), H1 2018

Dormant Products, H1 2018 (Contd..4), H1 2018

Dormant Products, H1 2018 (Contd..5), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aprea AB
  • CanBas Co Ltd
  • Cotinga Pharmaceuticals Inc
  • Innovation Pharmaceuticals Inc
  • ORCA Therapeutics BV
  • OSE Immunotherapeutics
  • Quark Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll